The production of radiopharmaceuticals as compared to traditional pharmaceuticals is a multifaceted procedure and requires specialized facilities, equipment and operational expertise. Further, owing to its inherent hazardous nature, radiopharmaceuticals have a complex regulatory market authorization process. Consequently, a number of innovator companies have demonstrated a preference for outsourcing radiopharmaceutical manufacturing to contract service providers.
To order this 320+ page report, which features 45+ figures and 100+ tables, please visit this – https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html
The USD 6+ billion (by 2030) financial opportunity associated with nuclear medicine and radiopharmaceuticals manufacturing, has been analyzed across the following segments:
Target Disease Indication
- Breast Cancer
- Chronic Lymphocytic Leukemia
- Colorectal Cancer
- Head and Neck Cancer
- Lung Cancer
- Lupus Nephritis
- Melanoma
- Multiple Myeloma
- Primary Sjögren's Syndrome
- Others
Target Immune Checkpoint
- B7-H3
- CD38
- CD40
- CD47
- Others
Mechanism of Action
- Inhibitory
- Stimulatory
Therapeutic Modality
- Monoclonal Antibody
- Small Molecule
Type of Therapy
- Monotherapy
- Combination Therapy
Route of Administration
- Intravenous
- Subcutaneous
- Others
Key Geographical Regions
- North America
- Europe
- Asia-Pacific and the Rest of the World
The Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030” report features the following companies, which we identified to be key players in this domain:
- Advanced Accelerator Applications
- Belgian Nuclear Research Center (SCK•CEN)
- Cardinal Health
- China Isotope & Radiation Corporation
- Curium Pharma
- DuChemBio
- Eckert & Ziegler
- Eczacibasi-Monrol
- GE Healthcare
- Jubilant DraxImage
- Lantheus Medical Imaging
- Nihon Medi-Physics
- Nordion
- PETNET Solutions
- SinoTau Pharmaceuticals
- SOFIE
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Current Market Landscape
5. Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Current Market Landscape
6. Nuclear Medicine and Radiopharmaceuticals Manufacturers in North America
7. Nuclear Medicine and Radiopharmaceuticals Manufacturers in Europe
8. Nuclear Medicine and Radiopharmaceuticals Manufacturers in Asia-Pacific And Rest of The World
9. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Company Competitiveness Analysis
10. Partnerships and Collaborations
11. Production and Supply Chain of Medical Isotope Molybdenum-99 (Technetium-99m)
12. Market Forecast and Opportunity Analysis
13. Concluding Remarks
14. Executive Insights
15. Appendix 1: Tabulated Data
16. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
